Generate Biomedicines 与 Zealand Pharma 合作开发肥胖治疗药物,Bloomberg 报道聚焦疗效、耐受性和便利性。多特异性蛋白的潜力在于单一治疗中针对多个疾病机制。Generate 按目标生物功能设计蛋白而非筛选现有分子,并让实验结果反馈模型以改进后续设计。
@Bloomberg's Madison Muller (@g0ingmad) reports on our collaboration with Zealand Pharma amid intensifying competition in obesity drug development.
Madison looks at the search for improved effectiveness, tolerability, and convenience, and the potential for multispecific proteins to address several disease mechanisms within one treatment.
She explains what we bring to that effort: designing proteins around desired biological functions rather than screening existing molecules, with experiments feeding back into our models to improve subsequent designs.
Read the story → https://lnkd.in/gFyg57HA
来源:Generate:Biomedicines · x.com